Tectonic Therapeutic, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of therapeutic proteins and antibodies that modulate the activity of G protein-coupled receptors (GPCR). The company is headquartered in Watertown, Massachusetts and currently employs 51 full-time employees. The company went IPO on 2018-06-21. The firm is focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs). Leveraging its technology platform called GEODe (GPCRs Engineered for Optimal Discovery), the Company is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery and harness the human body to modify the course of disease. The Company’s lead asset, TX000045 (TX45), is a Fc-relaxin fusion molecule that activates the RXFP1 receptor, the GPCR target of the hormone relaxin. TX45 is being evaluated in Phase Ia/Ib clinical trials as a potential treatment for Group 2 Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (HFpEF). TX002100 (TX2100) is its second development candidate for the treatment of Hereditary Hemorrhagic Telangiectasia (HHT).
Follow-Up Questions
Tectonic Therapeutic Inc 'in CEO'su kimdir?
Dr. Alise Reicin 2024 'den beri şirketle birlikte olan Tectonic Therapeutic Inc 'in President 'ıdır.
TECX hissesinin fiyat performansı nasıl?
TECX 'in mevcut fiyatı $18.89 'dir, son işlem günde 9.47% increased etti.
Tectonic Therapeutic Inc için ana iş temaları veya sektörler nelerdir?
Tectonic Therapeutic Inc Biotechnology endüstrisine ait ve sektör Health Care 'dir
Wall Street analistlerine göre, 10 analist Tectonic Therapeutic Inc için analist derecelendirmeleri gerçekleştirdi, bunlar 3 güçlü al, 10 al, 1 tut, 0 sat ve 3 güçlü sat içermektedir